Olema Pharmaceuticals, Inc. Stock price

Equities

OLMA

US68062P1066

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-01 pm EST 5-day change 1st Jan Change
14.8 USD +19.35% Intraday chart for Olema Pharmaceuticals, Inc. +9.71% +5.49%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Enjoy this offer
* See conditions on site
Sales 2023 * - Sales 2024 * - Capitalization 813M
Net income 2023 * -94M Net income 2024 * -114M EV / Sales 2023 * -
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 * -
P/E ratio 2023 *
-6.99 x
P/E ratio 2024 *
-6.76 x
Employees 70
Yield 2023 *
-
Yield 2024 *
-
Free-Float 95.32%
More Fundamentals * Assessed data
Dynamic Chart
Citigroup Initiates Olema Pharmaceuticals at Buy With $20 Price Target MT
Olema Pharmaceuticals, Inc. Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate CI
Olema Pharmaceuticals, Inc.(NasdaqGS:OLMA) added to NASDAQ Biotechnology Index CI
Olema Pharmaceuticals, Inc. Announces Palazestrant Demonstrates Attractive Combinability with Cdk4/6 Inhibitors Ribociclib and Palbociclib in Phase 1B/2 Studies CI
Transcript : Olema Pharmaceuticals, Inc. Presents at The 6th Annual Evercore ISI HealthCONx Conference, Nov-29-2023 01:20 PM
Olema Pharmaceuticals Insider Sold Shares Worth $269,656, According to a Recent SEC Filing MT
Olema Pharmaceuticals Insider Sold Shares Worth $824,134, According to a Recent SEC Filing MT
Olema Pharmaceuticals Insider Sold Shares Worth $196,233, According to a Recent SEC Filing MT
Olema Pharmaceuticals Insider Sold Shares Worth $209,296, According to a Recent SEC Filing MT
Olema Pharmaceuticals Insider Sold Shares Worth $117,740, According to a Recent SEC Filing MT
Olema Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Olema Pharmaceuticals Insider Sold Shares Worth $379,450, According to a Recent SEC Filing MT
JPMorgan Adjusts Olema Pharmaceuticals' Price Target to $25 From $19, Maintains Overweight Rating MT
Canaccord Genuity Adjusts Olema Pharmaceuticals' Price Target to $22 From $16, Maintains Buy Rating MT
Olema Pharmaceuticals, Inc. Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant CI
More news
1 day+19.35%
1 week+9.71%
Current month+19.35%
1 month-2.82%
3 months+1.51%
6 months+39.49%
Current year+5.49%
More quotes
1 week
11.94
Extreme 11.94
15.05
1 month
11.94
Extreme 11.94
16.78
Current year
10.82
Extreme 10.82
16.78
1 year
3.00
Extreme 3
17.79
3 years
2.00
Extreme 2
50.98
5 years
2.00
Extreme 2
60.27
10 years
2.00
Extreme 2
60.27
More quotes
Managers TitleAgeSince
Founder 86 06-08-06
Chief Executive Officer 58 20-08-31
Founder 54 06-08-06
Members of the board TitleAgeSince
Chairman 62 20-07-31
Director/Board Member 55 23-10-15
Director/Board Member 66 12-12-31
More insiders
Date Price Change Volume
24-03-01 14.8 +19.35% 1,753,484
24-02-29 12.4 -4.39% 592,910
24-02-28 12.97 -5.47% 457,151
24-02-27 13.72 +1.40% 403,838
24-02-26 13.53 +0.30% 401,130

Delayed Quote Nasdaq, March 01, 2024 at 04:00 pm EST

More quotes
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of targeted therapies for women's cancers. Its lead product candidate, OP-1250, is an oral therapy with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). The Company's OP-1250 is an oral small molecule clinical-stage product candidate for the treatment of endocrine-driven cancers. OP-1250, both as a monotherapy and in combination with inhibitors of cyclin-dependent kinase four and six (CDK4/6) demonstrated robust tumor shrinkage in several xenograft models, including ESR1 and PIK3CA mutations and central nervous system (CNS), metastasis. It is in the Phase I/ II clinical trial, and in Phase Ib/ II combination with palbociclib, in patients with metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
14.8 USD
Average target price
24.88 USD
Spread / Average Target
+68.07%
Consensus
  1. Stock
  2. Equities
  3. Stock Olema Pharmaceuticals, Inc. - Nasdaq
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW